Total and regional lung deposition of terbutaline sulphate inhaled via a pressurised MDI or via Turbuhaler®

  • Borgström L
  • Newman S
  • 4


    Mendeley users who have this article in their library.
  • 68


    Citations of this article.


The deposition patterns of terbutaline sulphate delivered from pressurized metered dose inhaler (MDI) and Turbuhaler®have been compared by gamma scintigraphy. The radionuclide99mTc was used to label the formulations, and 1 mg terbutaline sulphate was subsequently inhaled from each device in a randomized cross-over fashion by eight healthy volunteers. Both devices were operated at their respective optimal inhalation flow rates. From the pressurised MDI, a mean 16.7% of the dose was deposited in the lungs (range 6.1-30.0%), compared to a mean 21.4% (range 14.1-30.8%) from Turbuhaler®. If the Turbuhaler®data were corrected for an observed mismatch in the size distributions of radiolabel and unlabelled drug, then the mean lung deposition from Turbuhaler®would be 29.3% of the dose. The distribution of radiolabel within the lungs was similar for each device, but oropharyngeal deposition was significantly reduced for Turbuhaler®(P < 0.01). It is concluded that pressurized MDI and Turbuhaler®produce broadly similar regional deposition in the lungs, but that the inter-subject variability of deposition is less for Turbuhaler®. © 1993.

Author-supplied keywords

  • 99mTc labeling
  • Asthma therapy
  • Gamma scintigraphy
  • Powder inhaler
  • Pressurised MDI
  • Terbutaline sulfate

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Lars Borgström

  • Stephen Newman

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free